EXPERIENCE WITH THE ROSINSULIN C IN COMBINATION WITH ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN ROUTINE CLINICAL PRACTICE

This study aimed to estimate the efficacy and safety of intermediate-acting insulin Rosinsulin C in patients with type 2 diabetes mellitus inadequately controlled with oral antidiabetic drugs.
The present study is a 6-month, prospective, uncontrolled, clinical experience evaluation study using insulin Rosinsulin С for type 2 diabetes patients in daily clinical practice. Episodes of hypoglycaemia, adverse events were recorded. The study included 28 patients with type 2 diabetes, 4 men and 24 women who treated with metformin in combination with sulfonylureas in the highest dose. Indicators of glycosylated hemoglobin (HbA1c) of 8 to 14%, the median HbA1c was 11 (10; 13)% of patients age 65 (57; 72) years, body mass index – 33 (30; 35) kg/m2, waist circumference – 105 (99; 111) cm, diabetes duration – 7 (2; 11) years. With the introduction of Rosinsulin С cartridges carried pen Autopen. At the start of the study and after 3 and 6 months, determined the level of HbA1c, fasting plasma glucose.
After 6 months' treatment with Rosinsulin С in combination with oral antidiabetic drugs HbA1c was significantly lowered (–3%) (p = 0,001), fasting plasma glucose level decreased by 5 mmol/L (p = 0,001). There was not severe hypoglycemia during the observation period.
This research showed that Rosinsulin C is effective and safe in the treatment of patients with type 2 diabetes who were decompensated with oral antidiabetic drugs and can be recommended for use as the initiation of insulin therapy in routine clinical practice.

1. Ametov A.S., Karpova Ye.V. Russian Journal of Medicine, 2008, vol. 16, no. 9, pp. 1000–1006 (in Russian).

2. Skyler J.S., Bergenstal R., Bonow R.O., Buse J. et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Tials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation, 2009, no. 119, pp. 351–357.

3. Suntsov Yu.I. Diabetes Mellitus, 2012, issue 1, pp. 6–9 (in Russian).

4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N. Engl. J. Med., 2008, 358, pp. 2545–2559.

5. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med., 2008, 358, pp. 2560–2572.

6. Dedov I.I., Shestakova M.V. Diabetes Mellitus, 2010, issue 5, pp. 9–16 (in Russian).